nach oben

Irish Journal of Medical Science (1971 -)

Erschienen in:

01.09.2015 | Review Article

Ongoing challenges in the treatment of adenoid cystic carcinoma of the head and neck

verfasst von: T. Subramaniam, P. Lennon, J. P. O’Neill

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Adenoid cystic carcinoma is a malignant tumour of major and minor salivary glands. Distant metastasis and poor survival are persistent in the literature, with recent publications aimed at understanding molecular pathogenesis and development of pharmaceutical therapeutic options.

Aim

Provide an update of recent studies in the management of adenoid cystic carcinoma of the head and neck.

Methods

Literature search using Medline, Scopus, Google Scholar, the Cochrane Database of Systematic Reviews and the Cochrane central register of controlled trials for articles on adenoid cystic carcinoma from January 2005 to January 2015.

Conclusion

Adenoid cystic carcinoma is characterized by a slow growing mass, with distant metastasis independent of local or regional control. Primary tumour resection remains the preferred option with radiotherapy having an adjuvant role. Recent advances have been made with novel targeted therapies however, limited to clinical trials and advanced disease.

Foote FW Jr, Frazell EL (1953) Tumors of the major salivary glands. Cancer 6(6):1065–1133CrossRefPubMed

Ellington CL, Goodman M, Kono SA, Grist W, Wadsworth T, Chen AY et al (2012) Adenoid cystic carcinoma of the head and neck: incidence and survival trends based on 1973–2007 surveillance, epidemiology, and end results data. Cancer 118(18):4444–4451CrossRefPubMed

Li N, Xu L, Zhao H, El-Naggar AK, Sturgis EM (2012) A comparison of the demographics, clinical features, and survival of patients with adenoid cystic carcinoma of major and minor salivary glands versus less common sites within the surveillance, epidemiology, and end results registry. Cancer 118(16):3945–3953PubMedCentralCrossRefPubMed

Matsuba HM, Thawley SE, Simpson JR, Levine LA, Mauney M (1984) Adenoid cystic carcinoma of major and minor salivary gland origin. Laryngoscope 94(10):1316–1318CrossRefPubMed

Spiro RH, Huvos AG, Strong EW (1974) Adenoid cystic carcinoma of salivary origin. A clinicopathologic study of 242 cases. Am J Surg 128(4):512–520CrossRefPubMed

Saghravanian N, Mohtasham N, Jafarzadeh H (2009) Comparison of immunohistochemical markers between adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma. J Oral Sci 51(4):509–514CrossRefPubMed

Simpson RH, Skalova A, Di Palma S, Leivo I (2014) Recent advances in the diagnostic pathology of salivary carcinomas. Virchows Archiv Int J Pathol 465(4):371–384CrossRef

IARC (2015) International classification of diseases for oncology, ICD-O-3, 8200/3 adenoid cystic carcinoma. WHO. http://codes.iarc.fr/code/282. Accessed 6 Jan 2015

Jaso J, Malhotra R (2011) Adenoid cystic carcinoma. Arch Pathol Lab Med 135(4):511–515PubMed

10.

Seethala RR, Hunt JL, Baloch ZW, Livolsi VA, Leon Barnes E (2007) Adenoid cystic carcinoma with high-grade transformation: a report of 11 cases and a review of the literature. Am J Surg Pathol 31(11):1683–1694CrossRefPubMed

11.

Ellis GL, Auclair PL (2008) Tumors of the salivary glands. Atlas of tumor pathology; 4th series, Fascicle 9. ARP Press, Silver Spring (MD), pp 225–259

12.

Edwards PC, Bhuiya T, Kelsch RD (2004) Assessment of p63 expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and basal cell and canalicular adenomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 97(5):613–619CrossRefPubMed

13.

Edwards PC, Bhuiya T, Kelsch RD (2003) C-kit expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and monomorphic adenoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95(5):586–593CrossRefPubMed

14.

Skalova A, Simpson RH, Lehtonen H, Leivo I (1997) Assessment of proliferative activity using the MIB1 antibody help to distinguish polymorphous low grade adenocarcinoma from adenoid cystic carcinoma of salivary glands. Pathol Res Pract 193(10):695–703CrossRefPubMed

15.

Persson M, Andren Y, Mark J, Horlings HM, Persson F, Stenman G (2009) Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci USA 106(44):18740–18744PubMedCentralCrossRefPubMed

16.

Stenman G (2013) Fusion oncogenes in salivary gland tumors: molecular and clinical consequences. Head Neck Pathol 7(Suppl 1):S12–S19CrossRefPubMed

17.

Brill LB 2nd, Kanner WA, Fehr A, Andren Y, Moskaluk CA, Loning T et al (2011) Analysis of MYB expression and MYB–NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms. Modern Pathol Off J US Can Acad Pathol 24(9):1169–1176

18.

Szanto PA, Luna MA, Tortoledo ME, White RA (1984) Histologic grading of adenoid cystic carcinoma of the salivary glands. Cancer 54(6):1062–1069CrossRefPubMed

19.

Perzin KH, Gullane P, Clairmont AC (1978) Adenoid cystic carcinomas arising in salivary glands: a correlation of histologic features and clinical course. Cancer 42(1):265–282CrossRefPubMed

20.

Patey DH, Thackray AC, Keeling DH (1965) Malignant disease of the parotid. Br J Cancer 19(4):712–737PubMedCentralCrossRefPubMed

21.

Thackray AC, Lucas RB (1960) The histology of cylindroma of mucous gland origin. Br J Cancer 14:612–620PubMedCentralCrossRefPubMed

22.

Seethala RR (2009) An update on grading of salivary gland carcinomas. Head Neck Pathol 3(1):69–77PubMedCentralCrossRefPubMed

23.

van Weert S, van der Waal I, Witte BI, Leemans CR, Bloemena E (2015) Histopathological grading of adenoid cystic carcinoma of the head and neck: analysis of currently used grading systems and proposal for a simplified grading scheme. Oral Oncol 51(1):71–76CrossRefPubMed

24.

Ho AS, Kannan K, Roy DM, Morris LG, Ganly I, Katabi N et al (2013) The mutational landscape of adenoid cystic carcinoma. Nat Genet 45(7):791–798CrossRefPubMed

25.

Wolffe AP (2001) Chromatin remodeling: why it is important in cancer. Oncogene 20(24):2988–2990CrossRefPubMed

26.

Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A et al (2010) Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463(7279):360–363PubMedCentralCrossRefPubMed

27.

Tsurusaki Y, Okamoto N, Ohashi H, Kosho T, Imai Y, Hibi-Ko Y et al (2012) Mutations affecting components of the SWI/SNF complex cause Coffin–Siris syndrome. Nat Genet 44(4):376–378CrossRefPubMed

28.

Binmadi NO, Yang YH, Zhou H, Proia P, Lin YL, De Paula AM et al (2012) Plexin-B1 and semaphorin 4D cooperate to promote perineural invasion in a RhoA/ROK-dependent manner. Am J Pathol 180(3):1232–1242PubMedCentralCrossRefPubMed

29.

Stephens PJ, Davies HR, Mitani Y, Van Loo P, Shlien A, Tarpey PS et al (2013) Whole exome sequencing of adenoid cystic carcinoma. J Clin Investig 123(7):2965–2968PubMedCentralCrossRefPubMed

30.

Oswald F, Kostezka U, Astrahantseff K, Bourteele S, Dillinger K, Zechner U et al (2002) SHARP is a novel component of the Notch/RBP-Jkappa signalling pathway. EMBO J 21(20):5417–5426PubMedCentralCrossRefPubMed

31.

Barrett AW, Speight PM (2009) Perineural invasion in adenoid cystic carcinoma of the salivary glands: a valid prognostic indicator? Oral Oncol 45(11):936–940CrossRefPubMed

32.

Liebig C, Ayala G, Wilks JA, Berger DH, Albo D (2009) Perineural invasion in cancer: a review of the literature. Cancer 115(15):3379–3391CrossRefPubMed

33.

Teymoortash A, Zieger L, Hoch S, Pagenstecher A, Hofer MJ (2014) Distinct microscopic features of perineural invasion in adenoid cystic carcinoma of the head and neck. Histopathology 64(7):1037–1039CrossRefPubMed

34.

Amit M, Binenbaum Y, Trejo-Leider L, Sharma K, Ramer N, Ramer I et al (2014) International collaborative validation of intraneural invasion as a prognostic marker in adenoid cystic carcinoma of the head and neck. Head Neck 2014:7. doi:10.1002/hed.23710

35.

Amit M, Binenbaum Y, Sharma K, Ramer N, Ramer I, Agbetoba A et al (2014) Analysis of failure in patients with adenoid cystic carcinoma of the head and neck. An international collaborative study. Head Neck 36(7):998–1004CrossRefPubMed

36.

Gao M, Hao Y, Huang MX, Ma DQ, Luo HY, Gao Y et al (2013) Clinicopathological study of distant metastases of salivary adenoid cystic carcinoma. Int J Oral Maxillofac Surg 42(8):923–928CrossRefPubMed

37.

Shingaki S, Kanemaru S, Oda Y, Niimi K, Mikami T, Funayama A et al (2014) Distant metastasis and survival of adenoid cystic carcinoma after definitive treatment. J Oral Maxillofac Surg Med Pathol 26(3):312–316CrossRef

38.

Chen AM, Bucci MK, Weinberg V, Garcia J, Quivey JM, Schechter NR et al (2006) Adenoid cystic carcinoma of the head and neck treated by surgery with or without postoperative radiation therapy: prognostic features of recurrence. Int J Radiat Oncol Biol Phys 66(1):152–159CrossRefPubMed

39.

Shen C, Xu T, Huang C, Hu C, He S (2012) Treatment outcomes and prognostic features in adenoid cystic carcinoma originated from the head and neck. Oral Oncol 48(5):445–449CrossRefPubMed

40.

Bhayani MK, Yener M, El-Naggar A, Garden A, Hanna EY, Weber RS et al (2012) Prognosis and risk factors for early-stage adenoid cystic carcinoma of the major salivary glands. Cancer 118(11):2872–2878CrossRefPubMed

41.

Lloyd S, Yu JB, Wilson LD, Decker RH (2011) Determinants and patterns of survival in adenoid cystic carcinoma of the head and neck, including an analysis of adjuvant radiation therapy. Am J Clin Oncol 34(1):76–81CrossRefPubMed

42.

Mizoe JE, Hasegawa A, Jingu K, Takagi R, Bessyo H, Morikawa T et al (2012) Results of carbon ion radiotherapy for head and neck cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol 103(1):32–37CrossRef

43.

Takagi M, Demizu Y, Hashimoto N, Mima M, Terashima K, Fujii O et al (2014) Treatment outcomes of particle radiotherapy using protons or carbon ions as a single-modality therapy for adenoid cystic carcinoma of the head and neck. Radiother Oncol J Eur Soc Ther Radiol Oncol 113(3):364–370CrossRef

44.

Tsujii H, Kamada T (2012) A review of update clinical results of carbon ion radiotherapy. Jpn J Clin Oncol 42(8):670–685PubMedCentralCrossRefPubMed

45.

Schlaff CD, Krauze A, Belard A, O’Connell JJ, Camphausen KA (2014) Bringing the heavy: carbon ion therapy in the radiobiological and clinical context. Radiat Oncol 9(1):88PubMedCentralCrossRefPubMed

46.

Spiro RH (1997) Distant metastasis in adenoid cystic carcinoma of salivary origin. Am J Surg 174(5):495–498CrossRefPubMed

47.

Vander Poorten V, Hunt J, Bradley PJ, Haigentz M Jr, Rinaldo A, Mendenhall WM et al (2014) Recent trends in the management of minor salivary gland carcinoma. Head Neck 36(3):444–455CrossRefPubMed

48.

Sung MW, Kim KH, Kim JW, Min YG, Seong WJ, Roh JL et al (2003) Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 129(11):1193–1197CrossRefPubMed

49.

Maruya S, Namba A, Matsubara A, Kakehata S, Takeda I, Shirasaki T et al (2006) Salivary gland carcinoma treated with concomitant chemoradiation with intraarterial cisplatin and docetaxel. Int J Clin Oncol 11(5):403–406CrossRefPubMed

50.

Samant S, van den Brekel MW, Kies MS, Wan J, Robbins KT, Rosenthal DI et al (2012) Concurrent chemoradiation for adenoid cystic carcinoma of the head and neck. Head Neck 34(9):1263–1268CrossRefPubMed

51.

Cerda T, Sun XS, Vignot S, Marcy PY, Baujat B, Baglin AC et al (2014) A rationale for chemoradiation (vs radiotherapy) in salivary gland cancers? On behalf of the REFCOR (French rare head and neck cancer network). Crit Rev Oncol Hematol 91(2):142–158CrossRefPubMed

52.

Laurie SAAL, Matthew GF, Sherman E, Pfister DG (2010) Systematic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary gland; a systematic review. Lancet Oncol 12(8):815–824CrossRefPubMed

53.

Amit M, Binenbaum Y, Sharma K, Ramer N, Ramer I, Agbetoba A et al (2014) Incidence of cervical lymph node metastasis and its association with outcomes in patients with adenoid cystic carcinoma. An international collaborative study. Head Neck

54.

Lee SY, Kim BH, Choi EC (2014) Nineteen-year oncologic outcomes and the benefit of elective neck dissection in salivary gland adenoid cystic carcinoma. Head Neck 36(12):1796–1801CrossRefPubMed

55.

Min R, Siyi L, Wenjun Y, Ow A, Lizheng W, Minjun D et al (2012) Salivary gland adenoid cystic carcinoma with cervical lymph node metastasis: a preliminary study of 62 cases. Int J Oral Maxillofac Surg 41(8):952–957CrossRefPubMed

56.

Fordice J, Kershaw C, El-Naggar A, Goepfert H (1999) Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg 125(2):149–152CrossRefPubMed

57.

Nobis CP, Rohleder NH, Wolff KD, Wagenpfeil S, Scherer EQ, Kesting MR (2014) Head and neck salivary gland carcinomas—elective neck dissection, yes or no? J Oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg 72(1):205–210CrossRef

58.

US National Institutes of Health (2015) ClinicalTrials.gov. https://clinicaltrials.gov/ct2/results?term=Adenoid+cystic+carcinoma&pg=5. Accessed 11 Jan 2015

59.

Tang Y, Liang X, Zheng M, Zhu Z, Zhu G, Yang J et al (2010) Expression of c-kit and slug correlates with invasion and metastasis of salivary adenoid cystic carcinoma. Oral Oncol 46(4):311–316CrossRefPubMed

60.

Pfeffer MR, Talmi Y, Catane R, Symon Z, Yosepovitch A, Levitt M (2007) A phase II study of imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol 43(1):33–36CrossRefPubMed

61.

Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX et al (2005) Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol Off J Am Soc Clin Oncol 23(3):585–590CrossRef

62.

Ghosal N, Mais K, Shenjere P, Julyan P, Hastings D, Ward T et al (2011) Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma. Br J Oral Maxillofac Surg 49(7):510–515CrossRefPubMed

63.

Huang Y, Yu T, Fu X, Chen J, Liu Y, Li C et al (2013) EGFR inhibition prevents in vitro tumor growth of salivary adenoid cystic carcinoma. BMC Cell Biol 14:13PubMedCentralCrossRefPubMed

64.

Jakob JA, Kies MS, Glisson BS, Kupferman ME, Liu DD, Lee JJ et al (2014) Phase II study of gefitinib in patients with advanced salivary gland cancers. Head Neck. doi:10.1002/hed.23647

65.

Locati LD, Bossi P, Perrone F, Potepan P, Crippa F, Mariani L et al (2009) Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 45(7):574–578CrossRefPubMed

66.

Hitre E, Budai B, Takacsi-Nagy Z, Rubovszky G, Toth E, Remenar E et al (2013) Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial. Br J Cancer 109(5):1117–1122PubMedCentralCrossRefPubMed

67.

Agulnik M, Cohen EW, Cohen RB, Chen EX, Vokes EE, Hotte SJ et al (2007) Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol Off J Am Soc Clin Oncol 25(25):3978–3984CrossRef

68.

Chau NG, Hotte SJ, Chen EX, Chin SF, Turner S, Wang L et al (2012) A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Ann Oncol 23(6):1562–1570CrossRefPubMed

69.

Ivanov SV, Panaccione A, Brown B, Guo Y, Moskaluk CA, Wick MJ et al (2013) TrkC signaling is activated in adenoid cystic carcinoma and requires NT-3 to stimulate invasive behavior. Oncogene 32(32):3698–3710CrossRefPubMed

70.

Younes MN, Park YW, Yazici YD, Gu M, Santillan AA, Nong X et al (2006) Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model. Mol Cancer Ther 5(11):2696–2705CrossRefPubMed

71.

Kim DW, Oh DY, Shin SH, Kang JH, Cho BC, Chung JS et al (2014) A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma. BMC Cancer 14:795PubMedCentralCrossRefPubMed

72.

Wetterskog D, Wilkerson PM, Rodrigues DN, Lambros MB, Fritchie K, Andersson MK et al (2013) Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations. Histopathology 62(4):543–550CrossRefPubMed

73.

Carlson J, Licitra L, Locati L, Raben D, Persson F, Stenman G (2013) Salivary gland cancer: an update on present and emerging therapies. Am Soc of Clin Oncol Educ Book 2013:257–263CrossRef

74.

Ramsay RG, Gonda TJ (2008) MYB function in normal and cancer cells. Nat Rev Cancer 8(7):523–534CrossRefPubMed

75.

Bell D, Roberts D, Karpowicz M, Hanna EY, Weber RS, El-Naggar AK (2011) Clinical significance of Myb protein and downstream target genes in salivary adenoid cystic carcinoma. Cancer Biol Ther 12(7):569–573PubMedCentralCrossRefPubMed

76.

Adenoid Cystic Carcinoma Reseach Foundation (2015) Therapeutic targets. http://www.accrf.org/research/therapeutic-targets. Accessed 11 Jan 2015

Titel: Ongoing challenges in the treatment of adenoid cystic carcinoma of the head and neck
verfasst von: T. Subramaniam
P. Lennon
J. P. O’Neill
Publikationsdatum: 01.09.2015
Verlag: Springer London
Erschienen in: Irish Journal of Medical Science (1971 -) / Ausgabe 3/2015
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-015-1298-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Ongoing challenges in the treatment of adenoid cystic carcinoma of the head and neck

Abstract

Background

Aim

Methods

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Background

Aim

Methods

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

The professionalisation of Irish medicine in the generations before Charles Lucas

Franciscus Cornelis Donders (1818–1889)

Securing the future of interventional radiology with lessons from the past

Protective effects of three remote ischemic conditioning procedures against renal ischemic/reperfusion injury in rat kidneys: a comparative study

Utility of CT head in the acute setting: value of contrast and non-contrast studies

Predicting mortality following hip fracture: an analysis of comorbidities and complications

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin